Phase I psilocybin safety trial ATMA

This Phase I open-label trial (n=14) studied the safety of psilocybin when administered to healthy participants enrolled in a psychedelic-assisted therapy training program. Participants ingested 25 mg of psilocybin extract, and vital signs, including heart rate, blood pressure, temperature, and ECG, were monitored throughout the study.

Adverse events were recorded at 2 days, 7 days, and 8 weeks following the psilocybin session. The trial aimed to collect physiological data and adverse events to help develop clinical screening protocols for psilocybin-assisted therapy, as well as assess the subjective effects of psilocybin at a dose of 25 mg.

Topic Safety Healthy Subjects
Compound Psilocybin
Country Canada
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

ATMA Journey Centers
ATMA Journey Centers was Canada’s first private therapy company to conduct legal psychedelic-assisted therapy using psilocybin.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.